Future studies should compare reprogramming rates across ccRCC tumors with different secondary mutations affecting histone methylation status, nucleosome remodeling complexes and ccRCC-specific signaling pathways (PI3K/AKT-mTOR). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.